Antibody Drugs: Technologies and Global Markets
Report Scope
This study offers a global view of the antibody drugs that have become key components of the pharmaceutical and biopharmaceutical markets. It analyzes and assesses therapeutic applications of monoclonal antibodies (mAbs) in human medicine, including the combination of mAbs when attached to cytotoxic agents such as antibody drug conjugates (ADCs).
BCC Research analyzed and made projections of each market and its applications, along with an analysis of the regulatory environment, new products and technological advances. Also included in the report are profiles of leading companies in the antibody drug industry, such as AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., and Merck KGaA.
Monoclonal antibodies are finding growing use in the treatment of chronic diseases. This report focuses on the global market for antibody drug products and provides an updated review of their applications in various disease sectors. The overall market for antibody drug products includes four primary areas of applications: autoimmune diseases; solid tumors; lymphoma and leukemia; and other diseases such as asthma, osteoporosis and cardiovascular diseases.
This report excludes polyclonal antibodies, screening kits and diagnostic uses of mAbs. It also excludes the research applications of mAbs and therapeutic antibodies for veterinary use. The report excludes antibody products for COVID-19 and vaccine-based products.
The market is segmented by geographical region: North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Regional analysis is further broken down by country as follows: North America—the U.S., Canada and Mexico; Europe—Germany, the U.K., France, Italy, Spain, and the Rest of Europe; Asia-Pacific—China, Japan, India, South Korea, Australia, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2021 and 2022 as the historic years, 2023 as the base year, and forecasts through 2029.
Report Includes
This study offers a global view of the antibody drugs that have become key components of the pharmaceutical and biopharmaceutical markets. It analyzes and assesses therapeutic applications of monoclonal antibodies (mAbs) in human medicine, including the combination of mAbs when attached to cytotoxic agents such as antibody drug conjugates (ADCs).
BCC Research analyzed and made projections of each market and its applications, along with an analysis of the regulatory environment, new products and technological advances. Also included in the report are profiles of leading companies in the antibody drug industry, such as AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., and Merck KGaA.
Monoclonal antibodies are finding growing use in the treatment of chronic diseases. This report focuses on the global market for antibody drug products and provides an updated review of their applications in various disease sectors. The overall market for antibody drug products includes four primary areas of applications: autoimmune diseases; solid tumors; lymphoma and leukemia; and other diseases such as asthma, osteoporosis and cardiovascular diseases.
This report excludes polyclonal antibodies, screening kits and diagnostic uses of mAbs. It also excludes the research applications of mAbs and therapeutic antibodies for veterinary use. The report excludes antibody products for COVID-19 and vaccine-based products.
The market is segmented by geographical region: North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Regional analysis is further broken down by country as follows: North America—the U.S., Canada and Mexico; Europe—Germany, the U.K., France, Italy, Spain, and the Rest of Europe; Asia-Pacific—China, Japan, India, South Korea, Australia, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2021 and 2022 as the historic years, 2023 as the base year, and forecasts through 2029.
Report Includes
- 76 data tables and 55 additional tables
- An updated review of the global market for antibody drugs
- Analyses of the global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
- Evaluation of the overall market for antibody drugs, and corresponding market share analysis by type, manufacturing process, application, and region
- Description of antibody functions and how they compare with antigens, and a discussion of monoclonal antibodies (mAbs), including their history, advantages and disadvantages, types, manufacturing technologies and applications
- Coverage of new approvals, recalls, safety alerts and clinical trials of mAbs, as well as technical issues related to human anti-mouse antibody (HAMA), and factors affecting mAB drugs
- An assessment of the major technologies for the formulation of antibody drugs and their relation to biotechnology, immunology, pharmaceuticals, and biodefense companies
- Discussions of the market dynamics, opportunities and challenges, as well as emerging technologies
- Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes
- Competitive intelligence, including companies’ market shares, recent M&A activity and venture funding
- Profiles of the leading companies, including F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., AbbVie Inc., Merck KGaA, and Amgen Inc.
CHAPTER 1 EXECUTIVE SUMMARY
Market Outlook
Scope of Report
Market Insights
CHAPTER 2 MARKET OVERVIEW
Antibodies and Antigens
Antibody Functions
Monoclonal Antibodies
History of Monoclonal Antibodies
Monoclonal Antibodies: Advantages and Disadvantages
Types of Monoclonal Antibodies
Manufacturing Technologies of Monoclonal Antibodies
Applications of Monoclonal Antibodies
CHAPTER 3 MARKET DYNAMICS
Drivers
Increasing Incidence of Cancer and Autoimmune Diseases
New Product Launches
Restraints
High Prices and Pricing Pressure
Side Effects and Limitations of mAbs
Opportunities
Licensing and Collaboration Agreements
Manufacturing Advances and Improving Product Yields
CHAPTER 4 REGULATORY ASPECTS
Regulatory Scenario
Price Controls
New Approvals of Monoclonal Antibodies
CHAPTER 5 EMERGING TECHNOLOGIES AND DEVELOPMENTS
Overview
Emerging Technologies
Bispecific Antibodies and Multi-Specific Antibodies
Antibody-Drug Conjugates
Antibody Fusion Proteins
AI and ML in Antibody Drug Engineering
CHAPTER 6 MARKET SEGMENTATION ANALYSIS
Segmentation Breakdown
Global Market for Antibody Drugs, by Antibody Type
Human Monoclonal Antibodies
Humanized Monoclonal Antibodies
Chimeric Monoclonal Antibodies
Murine Monoclonal Antibodies
Global Market for Antibody Drugs, by Manufacturing Process
Mammalian Cell Culture
Microbial Cell Fermentation
Global Market for Antibody Drugs, by Application
Market by Application
Autoimmune Diseases
Solid Tumors
Lymphoma, Leukemia and Multiple Myeloma
Others
Geographic Breakdown
Global Market for Antibody Drugs, by Region
Market Size and Forecast
North America
Europe
Asia-Pacific
Rest of the World (RoW)
CHAPTER 7 COMPETITIVE INTELLIGENCE
Competitive Landscape
Market Share for Human Monoclonal Antibodies
Market Share for Humanized Monoclonal Antibodies
Market Share for Chimeric Monoclonal Antibodies
CHAPTER 8 NEW DEVELOPMENTS AND CLINICAL TRIAL ACTIVITIES
New Developments and M&A Analysis
Clinical Trial Activities
Phase I Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
Phase IV Clinical Trials
CHAPTER 9 SUSTAINABILITY: AN ESG PERSPECTIVE IN THE ANTIBODY DRUGS MARKET
Sustainability in the Antibody Drugs Market
Understanding the ESG Data
Environmental Performance
Social Performance
Governance Performance
Concluding Remarks from BCC
CHAPTER 10 APPENDIX
Methodology
Sources
Acronyms
Company Profiles
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON SERVICES INC.
LILLY
MERCK KGAA
NOVARTIS AG
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
SANOFI
Market Outlook
Scope of Report
Market Insights
CHAPTER 2 MARKET OVERVIEW
Antibodies and Antigens
Antibody Functions
Monoclonal Antibodies
History of Monoclonal Antibodies
Monoclonal Antibodies: Advantages and Disadvantages
Types of Monoclonal Antibodies
Manufacturing Technologies of Monoclonal Antibodies
Applications of Monoclonal Antibodies
CHAPTER 3 MARKET DYNAMICS
Drivers
Increasing Incidence of Cancer and Autoimmune Diseases
New Product Launches
Restraints
High Prices and Pricing Pressure
Side Effects and Limitations of mAbs
Opportunities
Licensing and Collaboration Agreements
Manufacturing Advances and Improving Product Yields
CHAPTER 4 REGULATORY ASPECTS
Regulatory Scenario
Price Controls
New Approvals of Monoclonal Antibodies
CHAPTER 5 EMERGING TECHNOLOGIES AND DEVELOPMENTS
Overview
Emerging Technologies
Bispecific Antibodies and Multi-Specific Antibodies
Antibody-Drug Conjugates
Antibody Fusion Proteins
AI and ML in Antibody Drug Engineering
CHAPTER 6 MARKET SEGMENTATION ANALYSIS
Segmentation Breakdown
Global Market for Antibody Drugs, by Antibody Type
Human Monoclonal Antibodies
Humanized Monoclonal Antibodies
Chimeric Monoclonal Antibodies
Murine Monoclonal Antibodies
Global Market for Antibody Drugs, by Manufacturing Process
Mammalian Cell Culture
Microbial Cell Fermentation
Global Market for Antibody Drugs, by Application
Market by Application
Autoimmune Diseases
Solid Tumors
Lymphoma, Leukemia and Multiple Myeloma
Others
Geographic Breakdown
Global Market for Antibody Drugs, by Region
Market Size and Forecast
North America
Europe
Asia-Pacific
Rest of the World (RoW)
CHAPTER 7 COMPETITIVE INTELLIGENCE
Competitive Landscape
Market Share for Human Monoclonal Antibodies
Market Share for Humanized Monoclonal Antibodies
Market Share for Chimeric Monoclonal Antibodies
CHAPTER 8 NEW DEVELOPMENTS AND CLINICAL TRIAL ACTIVITIES
New Developments and M&A Analysis
Clinical Trial Activities
Phase I Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
Phase IV Clinical Trials
CHAPTER 9 SUSTAINABILITY: AN ESG PERSPECTIVE IN THE ANTIBODY DRUGS MARKET
Sustainability in the Antibody Drugs Market
Understanding the ESG Data
Environmental Performance
Social Performance
Governance Performance
Concluding Remarks from BCC
CHAPTER 10 APPENDIX
Methodology
Sources
Acronyms
Company Profiles
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON SERVICES INC.
LILLY
MERCK KGAA
NOVARTIS AG
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
SANOFI
LIST OF TABLES
Summary Table : Global Market for Antibody Drugs, by Region, Through 2029
Table 1 : Evolution of Monoclonal Antibodies, 1908-2024
Table 2 : Advantages and Disadvantages of Monoclonal Antibodies
Table 3 : Differences between Hybridoma and Recombinant Technologies
Table 4 : Incidence and Mortality Rates of Cancer Across Regions, 2022
Table 5 : Therapeutic Area Distribution of Approved Antibody Drugs, 2023*
Table 6 : Approved Antibody Products for Rare Autoimmune Diseases
Table 7 : Listed Pricing of Select Antibody Drugs in the U.S.
Table 8 : Newly Approved Monoclonal Antibodies, 2022–July 2024
Table 9 : Top Selling Antibody Drugs, 2023
Table 10 : Global Market for Antibody Drugs, by Antibody Type, Through 2029
Table 11 : Global Market for Human Monoclonal Antibodies, by Region, Through 2029
Table 12 : North American Market for Human Monoclonal Antibodies, by Country, Through 2029
Table 13 : European Market for Human Monoclonal Antibodies, by Country, Through 2029
Table 14 : Asia-Pacific Market for Human Monoclonal Antibodies, by Country, Through 2029
Table 15 : Global Market for Humanized Monoclonal Antibodies, by Region, Through 2029
Table 16 : North American Market for Humanized Monoclonal Antibodies, by Country, Through 2029
Table 17 : European Market for Humanized Monoclonal Antibodies, by Country, Through 2029
Table 18 : Asia-Pacific Market for Humanized Monoclonal Antibodies, by Country, Through 2029
Table 19 : Global Market for Chimeric Monoclonal Antibodies, by Region, Through 2029
Table 20 : North American Market for Chimeric Monoclonal Antibodies, by Country, Through 2029
Table 21 : European Market for Chimeric Monoclonal Antibodies, by Country, Through 2029
Table 22 : Asia-Pacific Market for Chimeric Monoclonal Antibodies, by Country, Through 2029
Table 23 : Global Market for Murine Monoclonal Antibodies, by Region, Through 2029
Table 24 : North American Market for Murine Monoclonal Antibodies, by Country, Through 2029
Table 25 : European Market for Murine Monoclonal Antibodies, by Country, Through 2029
Table 26 : Asia-Pacific Market for Murine Monoclonal Antibodies, by Country, Through 2029
Table 27 : Global Market for Antibody Drugs, by Manufacturing Process, Through 2029
Table 28 : Global Market for Antibody Drugs Produced by Mammalian Cell Culture, by Region, Through 2029
Table 29 : North American Market for Antibody Drugs Produced by Mammalian Cell Culture, by Country, Through 2029
Table 30 : European Market for Antibody Drugs Produced by Mammalian Cell Culture, by Country, Through 2029
Table 31 : Asia-Pacific Market for Antibody Drugs Produced by Mammalian Cell Culture, by Country, Through 2029
Table 32 : Global Market for Antibody Drugs Produced by Microbial Cell Fermentation, by Region, Through 2029
Table 33 : North American Market for Antibody Drugs Produced by Microbial Cell Fermentation, by Country, Through 2029
Table 34 : European Market for Antibody Drugs Produced by Microbial Cell Fermentation, by Country, Through 2029
Table 35 : Asia-Pacific Market for Antibody Drugs Produced by Microbial Cell Fermentation, by Country, Through 2029
Table 36 : Global Market for Antibody Drugs, by Application, Through 2029
Table 37 : Types of Autoimmune Diseases
Table 38 : Global Antibody Drugs Market for Autoimmune Diseases, by Region, Through 2029
Table 39 : North American Market for Antibody Drugs for Autoimmune Diseases, by Country, Through 2029
Table 40 : European Market for Antibody Drugs for Autoimmune Diseases, by Country, Through 2029
Table 41 : Asia-Pacific Market for Antibody Drugs for Autoimmune Diseases, by Country, Through 2029
Table 42 : Global Market for Antibody Drugs for Solid Tumors, by Region, Through 2029
Table 43 : North American Market for Antibody Drugs for Solid Tumors,, by Country, Through 2029
Table 44 : European Market for Antibody Drugs for Solid Tumors, by Country, Through 2029
Table 45 : Asia-Pacific Market for Antibody Drugs for Solid Tumors, by Country, Through 2029
Table 46 : Types of Leukemia
Table 47 : Global Market for Antibody Drugs for Lymphoma, Leukemia and Multiple Myeloma, by Region, Through 2029
Table 48 : North American Market for Antibody Drugs for Lymphoma, Leukemia and Multiple Myeloma, by Country, Through 2029
Table 49 : European Market for Antibody Drugs for Lymphoma, Leukemia and Multiple Myeloma, by Country, Through 2029
Table 50 : Asia-Pacific Market for Antibody Drugs for Lymphoma, Leukemia and Multiple Myeloma, by Country, Through 2029
Table 51 : Global Market for Antibody Drugs for Other Diseases, by Region, Through 2029
Table 52 : North American Market for Antibody Drugs for Other Diseases, by Country, Through 2029
Table 53 : European Market for Antibody Drugs for Other Diseases, by Country, Through 2029
Table 54 : Asia-Pacific Market for Antibody Drugs for Other Diseases, by Country, Through 2029
Table 55 : Global Market for Antibody Drugs, by Region, Through 2029
Table 56 : North American Market for Antibody Drugs, by Country, Through 2029
Table 57 : North American Market for Antibody Drugs, by Antibody Type, Through 2029
Table 58 : North American Market for Antibody Drugs, by Manufacturing Process, Through 2029
Table 59 : North American Market for Antibody Drugs, by Application, Through 2029
Table 60 : European Market for Antibody Drugs, by Country, Through 2029
Table 61 : European Market for Antibody Drugs, by Antibody Type, Through 2029
Table 62 : European Market for Antibody Drugs, by Manufacturing Process, Through 2029
Table 63 : European Market for Antibody Drugs, by Application, Through 2029
Table 64 : Asia-Pacific Market for Antibody Drugs, by Country, Through 2029
Table 65 : Asia-Pacific Market for Antibody Drugs, by Antibody Type, Through 2029
Table 66 : Asia-Pacific Market for Antibody Drugs, by Manufacturing Process, Through 2029
Table 67 : Asia-Pacific Market for Antibody Drugs, by Application, Through 2029
Table 68 : RoW Market for Antibody Drugs, by Antibody Type, Through 2029
Table 69 : RoW Market for Antibody Drugs, by Manufacturing Process, Through 2029
Table 70 : RoW Market for Antibody Drugs, by Application, Through 2029
Table 71 : Top Antibody Drug Companies, by Sales, 2023
Table 72 : Major Acquisitions and Alliances in the Antibody Drugs Industry, 2022–2024
Table 73 : Monoclonal Antibodies in Phase I Clinical TrialsMonoclonal Antibodies in Phase I Clinical Trials
Table 74 : Monoclonal Antibodies in Phase II Clinical Trials
Table 75 : Monoclonal Antibodies in Phase III Clinical Trials
Table 76 : Monoclonal Antibodies in Phase IV Clinical Trials
Table 77 : ESG Rankings for Major Antibody Drug Companies, 2024*
Table 78 : ESG: Environmental Overview
Table 79 : ESG: Social Factors Overview
Table 80 : ESG: Governance Overview
Table 81 : Report Sources
Table 82 : Glossary of Terms Used in the Antibody Drugs Market
Table 83 : AbbVie Inc.: Company Snapshot
Table 84 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 85 : AbbVie Inc.: Product Portfolio
Table 86 : AbbVie Inc.: News/Key Developments, 2022-2024
Table 87 : Amgen Inc.: Company Snapshot
Table 88 : Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 89 : Amgen Inc.: Product Portfolio
Table 90 : Amgen Inc.: News/Key Developments, 2022-2023
Table 91 : AstraZeneca: Company Snapshot
Table 92 : AstraZeneca: Financial Performance, FY 2022 and 2023
Table 93 : AstraZeneca: Product Portfolio
Table 94 : AstraZeneca: News/Recent Developments, 2021-2024
Table 95 : Bristol-Myers Squibb Co.: Company Snapshot
Table 96 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 97 : Bristol-Myers Squibb Co.: Product Portfolio
Table 98 : Bristol-Myers Squibb Co.: News/Key Developments, 2022-2023
Table 99 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 100 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 101 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 102 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023-2024
Table 103 : Johnson & Johnson Services Inc.: Company Snapshot
Table 104 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
Table 105 : Johnson & Johnson Services Inc.: Product Portfolio
Table 106 : Johnson & Johnson Services Inc.: News/Key Developments, 2022-2024
Table 107 : Lilly: Company Snapshot
Table 108 : Lilly: Financial Performance, FY 2022 and 2023
Table 109 : Lilly: Product Portfolio
Table 110 : Lilly: News/Key Developments, 2023-2024
Table 111 : Merck KGaA: Company Snapshot
Table 112 : Merck KGaA: Financial Performance, FY 2022 and 2023
Table 113 : Merck KGaA: Product Portfolio
Table 114 : Merck KGaA: News/Key Developments, 2022-2024
Table 115 : Novartis AG: Company Snapshot
Table 116 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 117 : Novartis AG: Product Portfolio
Table 118 : Novartis AG: News/Key Developments, 2022-2024
Table 119 : Pfizer Inc.: Company Snapshot
Table 120 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 121 : Pfizer Inc.: Product Portfolio
Table 122 : Pfizer Inc.: News/Key Developments, 2023
Table 123 : Regeneron Pharmaceuticals Inc.: Company Snapshot
Table 124 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 125 : Regeneron Pharmaceuticals Inc.: Product Portfolio
Table 126 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2023
Table 127 : Sanofi: Company Snapshot
Table 128 : Sanofi: Financial Performance, FY 2022 and 2023
Table 129 : Sanofi: Product Portfolio
Table 130 : Sanofi: News/Key Developments, 2022-2023
Summary Table : Global Market for Antibody Drugs, by Region, Through 2029
Table 1 : Evolution of Monoclonal Antibodies, 1908-2024
Table 2 : Advantages and Disadvantages of Monoclonal Antibodies
Table 3 : Differences between Hybridoma and Recombinant Technologies
Table 4 : Incidence and Mortality Rates of Cancer Across Regions, 2022
Table 5 : Therapeutic Area Distribution of Approved Antibody Drugs, 2023*
Table 6 : Approved Antibody Products for Rare Autoimmune Diseases
Table 7 : Listed Pricing of Select Antibody Drugs in the U.S.
Table 8 : Newly Approved Monoclonal Antibodies, 2022–July 2024
Table 9 : Top Selling Antibody Drugs, 2023
Table 10 : Global Market for Antibody Drugs, by Antibody Type, Through 2029
Table 11 : Global Market for Human Monoclonal Antibodies, by Region, Through 2029
Table 12 : North American Market for Human Monoclonal Antibodies, by Country, Through 2029
Table 13 : European Market for Human Monoclonal Antibodies, by Country, Through 2029
Table 14 : Asia-Pacific Market for Human Monoclonal Antibodies, by Country, Through 2029
Table 15 : Global Market for Humanized Monoclonal Antibodies, by Region, Through 2029
Table 16 : North American Market for Humanized Monoclonal Antibodies, by Country, Through 2029
Table 17 : European Market for Humanized Monoclonal Antibodies, by Country, Through 2029
Table 18 : Asia-Pacific Market for Humanized Monoclonal Antibodies, by Country, Through 2029
Table 19 : Global Market for Chimeric Monoclonal Antibodies, by Region, Through 2029
Table 20 : North American Market for Chimeric Monoclonal Antibodies, by Country, Through 2029
Table 21 : European Market for Chimeric Monoclonal Antibodies, by Country, Through 2029
Table 22 : Asia-Pacific Market for Chimeric Monoclonal Antibodies, by Country, Through 2029
Table 23 : Global Market for Murine Monoclonal Antibodies, by Region, Through 2029
Table 24 : North American Market for Murine Monoclonal Antibodies, by Country, Through 2029
Table 25 : European Market for Murine Monoclonal Antibodies, by Country, Through 2029
Table 26 : Asia-Pacific Market for Murine Monoclonal Antibodies, by Country, Through 2029
Table 27 : Global Market for Antibody Drugs, by Manufacturing Process, Through 2029
Table 28 : Global Market for Antibody Drugs Produced by Mammalian Cell Culture, by Region, Through 2029
Table 29 : North American Market for Antibody Drugs Produced by Mammalian Cell Culture, by Country, Through 2029
Table 30 : European Market for Antibody Drugs Produced by Mammalian Cell Culture, by Country, Through 2029
Table 31 : Asia-Pacific Market for Antibody Drugs Produced by Mammalian Cell Culture, by Country, Through 2029
Table 32 : Global Market for Antibody Drugs Produced by Microbial Cell Fermentation, by Region, Through 2029
Table 33 : North American Market for Antibody Drugs Produced by Microbial Cell Fermentation, by Country, Through 2029
Table 34 : European Market for Antibody Drugs Produced by Microbial Cell Fermentation, by Country, Through 2029
Table 35 : Asia-Pacific Market for Antibody Drugs Produced by Microbial Cell Fermentation, by Country, Through 2029
Table 36 : Global Market for Antibody Drugs, by Application, Through 2029
Table 37 : Types of Autoimmune Diseases
Table 38 : Global Antibody Drugs Market for Autoimmune Diseases, by Region, Through 2029
Table 39 : North American Market for Antibody Drugs for Autoimmune Diseases, by Country, Through 2029
Table 40 : European Market for Antibody Drugs for Autoimmune Diseases, by Country, Through 2029
Table 41 : Asia-Pacific Market for Antibody Drugs for Autoimmune Diseases, by Country, Through 2029
Table 42 : Global Market for Antibody Drugs for Solid Tumors, by Region, Through 2029
Table 43 : North American Market for Antibody Drugs for Solid Tumors,, by Country, Through 2029
Table 44 : European Market for Antibody Drugs for Solid Tumors, by Country, Through 2029
Table 45 : Asia-Pacific Market for Antibody Drugs for Solid Tumors, by Country, Through 2029
Table 46 : Types of Leukemia
Table 47 : Global Market for Antibody Drugs for Lymphoma, Leukemia and Multiple Myeloma, by Region, Through 2029
Table 48 : North American Market for Antibody Drugs for Lymphoma, Leukemia and Multiple Myeloma, by Country, Through 2029
Table 49 : European Market for Antibody Drugs for Lymphoma, Leukemia and Multiple Myeloma, by Country, Through 2029
Table 50 : Asia-Pacific Market for Antibody Drugs for Lymphoma, Leukemia and Multiple Myeloma, by Country, Through 2029
Table 51 : Global Market for Antibody Drugs for Other Diseases, by Region, Through 2029
Table 52 : North American Market for Antibody Drugs for Other Diseases, by Country, Through 2029
Table 53 : European Market for Antibody Drugs for Other Diseases, by Country, Through 2029
Table 54 : Asia-Pacific Market for Antibody Drugs for Other Diseases, by Country, Through 2029
Table 55 : Global Market for Antibody Drugs, by Region, Through 2029
Table 56 : North American Market for Antibody Drugs, by Country, Through 2029
Table 57 : North American Market for Antibody Drugs, by Antibody Type, Through 2029
Table 58 : North American Market for Antibody Drugs, by Manufacturing Process, Through 2029
Table 59 : North American Market for Antibody Drugs, by Application, Through 2029
Table 60 : European Market for Antibody Drugs, by Country, Through 2029
Table 61 : European Market for Antibody Drugs, by Antibody Type, Through 2029
Table 62 : European Market for Antibody Drugs, by Manufacturing Process, Through 2029
Table 63 : European Market for Antibody Drugs, by Application, Through 2029
Table 64 : Asia-Pacific Market for Antibody Drugs, by Country, Through 2029
Table 65 : Asia-Pacific Market for Antibody Drugs, by Antibody Type, Through 2029
Table 66 : Asia-Pacific Market for Antibody Drugs, by Manufacturing Process, Through 2029
Table 67 : Asia-Pacific Market for Antibody Drugs, by Application, Through 2029
Table 68 : RoW Market for Antibody Drugs, by Antibody Type, Through 2029
Table 69 : RoW Market for Antibody Drugs, by Manufacturing Process, Through 2029
Table 70 : RoW Market for Antibody Drugs, by Application, Through 2029
Table 71 : Top Antibody Drug Companies, by Sales, 2023
Table 72 : Major Acquisitions and Alliances in the Antibody Drugs Industry, 2022–2024
Table 73 : Monoclonal Antibodies in Phase I Clinical TrialsMonoclonal Antibodies in Phase I Clinical Trials
Table 74 : Monoclonal Antibodies in Phase II Clinical Trials
Table 75 : Monoclonal Antibodies in Phase III Clinical Trials
Table 76 : Monoclonal Antibodies in Phase IV Clinical Trials
Table 77 : ESG Rankings for Major Antibody Drug Companies, 2024*
Table 78 : ESG: Environmental Overview
Table 79 : ESG: Social Factors Overview
Table 80 : ESG: Governance Overview
Table 81 : Report Sources
Table 82 : Glossary of Terms Used in the Antibody Drugs Market
Table 83 : AbbVie Inc.: Company Snapshot
Table 84 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 85 : AbbVie Inc.: Product Portfolio
Table 86 : AbbVie Inc.: News/Key Developments, 2022-2024
Table 87 : Amgen Inc.: Company Snapshot
Table 88 : Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 89 : Amgen Inc.: Product Portfolio
Table 90 : Amgen Inc.: News/Key Developments, 2022-2023
Table 91 : AstraZeneca: Company Snapshot
Table 92 : AstraZeneca: Financial Performance, FY 2022 and 2023
Table 93 : AstraZeneca: Product Portfolio
Table 94 : AstraZeneca: News/Recent Developments, 2021-2024
Table 95 : Bristol-Myers Squibb Co.: Company Snapshot
Table 96 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 97 : Bristol-Myers Squibb Co.: Product Portfolio
Table 98 : Bristol-Myers Squibb Co.: News/Key Developments, 2022-2023
Table 99 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 100 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 101 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 102 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023-2024
Table 103 : Johnson & Johnson Services Inc.: Company Snapshot
Table 104 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
Table 105 : Johnson & Johnson Services Inc.: Product Portfolio
Table 106 : Johnson & Johnson Services Inc.: News/Key Developments, 2022-2024
Table 107 : Lilly: Company Snapshot
Table 108 : Lilly: Financial Performance, FY 2022 and 2023
Table 109 : Lilly: Product Portfolio
Table 110 : Lilly: News/Key Developments, 2023-2024
Table 111 : Merck KGaA: Company Snapshot
Table 112 : Merck KGaA: Financial Performance, FY 2022 and 2023
Table 113 : Merck KGaA: Product Portfolio
Table 114 : Merck KGaA: News/Key Developments, 2022-2024
Table 115 : Novartis AG: Company Snapshot
Table 116 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 117 : Novartis AG: Product Portfolio
Table 118 : Novartis AG: News/Key Developments, 2022-2024
Table 119 : Pfizer Inc.: Company Snapshot
Table 120 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 121 : Pfizer Inc.: Product Portfolio
Table 122 : Pfizer Inc.: News/Key Developments, 2023
Table 123 : Regeneron Pharmaceuticals Inc.: Company Snapshot
Table 124 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 125 : Regeneron Pharmaceuticals Inc.: Product Portfolio
Table 126 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2023
Table 127 : Sanofi: Company Snapshot
Table 128 : Sanofi: Financial Performance, FY 2022 and 2023
Table 129 : Sanofi: Product Portfolio
Table 130 : Sanofi: News/Key Developments, 2022-2023
LIST OF FIGURES
Summary Figure : Global Market Share of Antibody Drugs, by Region, 2023
Figure 1 : Dynamics of the Global Market for Antibody Drugs
Figure 2 : Emerging Technologies in the Antibody Drugs Market
Figure 3 : Global Market Share of Antibody Drugs, by Antibody Type, 2023
Figure 4 : Global Market for Human Monoclonal Antibodies, by Region, 2021–2029
Figure 5 : Global Market for Humanized Monoclonal Antibodies, by Region, 2021–2029
Figure 6 : Global Market for Chimeric Monoclonal Antibodies, by Region, 2021–2029
Figure 7 : Global Market for Murine Monoclonal Antibodies, by Region, 2021–2029
Figure 8 : Global Market Share of Antibody Drugs, by Manufacturing Process, 2023
Figure 9 : Global Market for Antibody Drugs Produced by Mammalian Cell Culture, by Region, 2021–2029
Figure 10 : Global Market for Antibody Drugs Produced by Microbial Cell Fermentation, by Region, 2021–2029
Figure 11 : Global Market Share of Antibody Drugs, by Application, 2023
Figure 12 : Global Antibody Drugs Market for Autoimmune Diseases, by Region, 2021–2029
Figure 13 : Global Market for Antibody Drugs for Solid Tumors, by Region, 2021–2029
Figure 14 : Global Market for Antibody Drugs for Lymphoma, Leukemia and Multiple Myeloma, by Region, 2021–2029
Figure 15 : Global Market for Antibody Drugs for Other Diseases, by Region, 2021?2029
Figure 16 : Global Market Share of Antibody Drugs, by Region, 2023
Figure 17 : Global Market for Antibody Drugs, by Region, 2021–2029
Figure 18 : North American Market Share of Antibody Drugs, by Country, 2023
Figure 19 : U.S. Market for Antibody Drugs, 2021?2029
Figure 20 : Canadian Market for Antibody Drugs, 2021?2029
Figure 21 : Mexican Market for Antibody Drugs, 2021?2029
Figure 22 : European Market Share of Antibody Drugs, by Country, 2023
Figure 23 : German Market for Antibody Drugs, 2021?2029
Figure 24 : French Market for Antibody Drugs, 2021?2029
Figure 25 : Italian Market for Antibody Drugs, 2021?2029
Figure 26 : Spanish Market for Antibody Drugs, 2021?2029
Figure 27 : U.K. Market for Antibody Drugs, 2021?2029
Figure 28 : Rest of Europe Market for Antibody Drugs, 2021?2029
Figure 29 : Asia-Pacific Market Share of Antibody Drugs, by Country, 2023
Figure 30 : Chinese Market for Antibody Drugs, 2021?2029
Figure 31 : Japanese Market for Antibody Drugs, 2021?2029
Figure 32 : Indian Market for Antibody Drugs, 2021?2029
Figure 33 : Australian Market for Antibody Drugs, 2021?2029
Figure 34 : South Korean Market for Antibody Drugs, 2021?2029
Figure 35 : Rest of Asia-Pacific Market for Antibody Drugs, 2021?2029
Figure 36 : Global Market Share of Human Monoclonal Antibodies, by Key Manufacturers/Suppliers, 2023
Figure 37 : Global Market Share of Humanized Monoclonal Antibodies, by Key Manufacturers/Suppliers, 2023
Figure 38 : Global Market Share of Chimeric Monoclonal Antibodies, by Key Manufacturers/Suppliers, 2023
Figure 39 : Key ESG Metrics of Antibody Drugs Companies
Figure 40 : AbbVie Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 41 : AbbVie Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 42 : Amgen Inc.: Revenue Shares, by Product, FY 2023
Figure 43 : Amgen Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 44 : AstraZeneca: Revenue Shares, by Therapy Areas, FY 2023
Figure 45 : AstraZeneca: Revenue Shares, by Region/Country, FY 2023
Figure 46 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2023
Figure 47 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2023
Figure 48 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2023
Figure 49 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2023
Figure 50 : Johnson & Johnson Services Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 51 : Johnson & Johnson Services Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 52 : Lilly: Revenue Shares, by Business Unit, FY 2023
Figure 53 : Lilly: Revenue Shares, by Country/Region, FY 2023
Figure 54 : Merck KGaA: Revenue Shares, by Business Unit, FY 2023
Figure 55 : Merck KGaA: Revenue Shares, by Country/Region, FY 2023
Figure 56 : Novartis AG: Revenue Shares, by Business Unit, FY 2023
Figure 57 : Novartis AG: Revenue Shares, by Country/Region, FY 2023
Figure 58 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 59 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 60 : Regeneron Pharmaceuticals Inc.: Revenue Shares, by Product Sales, FY 2023
Figure 61 : Regeneron Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 62 : Sanofi: Revenue Shares, by Business Unit, FY 2023
Figure 63 : Sanofi: Revenue Shares, by Country/ Region, FY 2023
Summary Figure : Global Market Share of Antibody Drugs, by Region, 2023
Figure 1 : Dynamics of the Global Market for Antibody Drugs
Figure 2 : Emerging Technologies in the Antibody Drugs Market
Figure 3 : Global Market Share of Antibody Drugs, by Antibody Type, 2023
Figure 4 : Global Market for Human Monoclonal Antibodies, by Region, 2021–2029
Figure 5 : Global Market for Humanized Monoclonal Antibodies, by Region, 2021–2029
Figure 6 : Global Market for Chimeric Monoclonal Antibodies, by Region, 2021–2029
Figure 7 : Global Market for Murine Monoclonal Antibodies, by Region, 2021–2029
Figure 8 : Global Market Share of Antibody Drugs, by Manufacturing Process, 2023
Figure 9 : Global Market for Antibody Drugs Produced by Mammalian Cell Culture, by Region, 2021–2029
Figure 10 : Global Market for Antibody Drugs Produced by Microbial Cell Fermentation, by Region, 2021–2029
Figure 11 : Global Market Share of Antibody Drugs, by Application, 2023
Figure 12 : Global Antibody Drugs Market for Autoimmune Diseases, by Region, 2021–2029
Figure 13 : Global Market for Antibody Drugs for Solid Tumors, by Region, 2021–2029
Figure 14 : Global Market for Antibody Drugs for Lymphoma, Leukemia and Multiple Myeloma, by Region, 2021–2029
Figure 15 : Global Market for Antibody Drugs for Other Diseases, by Region, 2021?2029
Figure 16 : Global Market Share of Antibody Drugs, by Region, 2023
Figure 17 : Global Market for Antibody Drugs, by Region, 2021–2029
Figure 18 : North American Market Share of Antibody Drugs, by Country, 2023
Figure 19 : U.S. Market for Antibody Drugs, 2021?2029
Figure 20 : Canadian Market for Antibody Drugs, 2021?2029
Figure 21 : Mexican Market for Antibody Drugs, 2021?2029
Figure 22 : European Market Share of Antibody Drugs, by Country, 2023
Figure 23 : German Market for Antibody Drugs, 2021?2029
Figure 24 : French Market for Antibody Drugs, 2021?2029
Figure 25 : Italian Market for Antibody Drugs, 2021?2029
Figure 26 : Spanish Market for Antibody Drugs, 2021?2029
Figure 27 : U.K. Market for Antibody Drugs, 2021?2029
Figure 28 : Rest of Europe Market for Antibody Drugs, 2021?2029
Figure 29 : Asia-Pacific Market Share of Antibody Drugs, by Country, 2023
Figure 30 : Chinese Market for Antibody Drugs, 2021?2029
Figure 31 : Japanese Market for Antibody Drugs, 2021?2029
Figure 32 : Indian Market for Antibody Drugs, 2021?2029
Figure 33 : Australian Market for Antibody Drugs, 2021?2029
Figure 34 : South Korean Market for Antibody Drugs, 2021?2029
Figure 35 : Rest of Asia-Pacific Market for Antibody Drugs, 2021?2029
Figure 36 : Global Market Share of Human Monoclonal Antibodies, by Key Manufacturers/Suppliers, 2023
Figure 37 : Global Market Share of Humanized Monoclonal Antibodies, by Key Manufacturers/Suppliers, 2023
Figure 38 : Global Market Share of Chimeric Monoclonal Antibodies, by Key Manufacturers/Suppliers, 2023
Figure 39 : Key ESG Metrics of Antibody Drugs Companies
Figure 40 : AbbVie Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 41 : AbbVie Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 42 : Amgen Inc.: Revenue Shares, by Product, FY 2023
Figure 43 : Amgen Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 44 : AstraZeneca: Revenue Shares, by Therapy Areas, FY 2023
Figure 45 : AstraZeneca: Revenue Shares, by Region/Country, FY 2023
Figure 46 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2023
Figure 47 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2023
Figure 48 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2023
Figure 49 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2023
Figure 50 : Johnson & Johnson Services Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 51 : Johnson & Johnson Services Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 52 : Lilly: Revenue Shares, by Business Unit, FY 2023
Figure 53 : Lilly: Revenue Shares, by Country/Region, FY 2023
Figure 54 : Merck KGaA: Revenue Shares, by Business Unit, FY 2023
Figure 55 : Merck KGaA: Revenue Shares, by Country/Region, FY 2023
Figure 56 : Novartis AG: Revenue Shares, by Business Unit, FY 2023
Figure 57 : Novartis AG: Revenue Shares, by Country/Region, FY 2023
Figure 58 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 59 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 60 : Regeneron Pharmaceuticals Inc.: Revenue Shares, by Product Sales, FY 2023
Figure 61 : Regeneron Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 62 : Sanofi: Revenue Shares, by Business Unit, FY 2023
Figure 63 : Sanofi: Revenue Shares, by Country/ Region, FY 2023
